Invivyd, Inc.
Invivyd, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. Its first authorized product, PEMGARDA (pemivibart), is designed to provide ongoing protection against SARS-CoV-2 despite viral evolution, and the company is also advancing additional product candidates such as VYD2311.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaSales of PEMGARDA in the U.S. through specialty distributors and direct accounts.
Discovery, preclinical, and clinical development of next-generation mAb candidates such as VYD2311.
Third-party logistics, customer service, and distribution infrastructure supporting product delivery.
Asiakkaat
Invivyd sells primarily into the U.S. healthcare channel, with PEMGARDA purchased by third-party specialty distributors and a smaller number of infusion centers, healthcare providers, and provider institutions. The end users are patients at risk of serious viral infectious disease, while the buying decision is driven by hospitals, clinics, and distributors that manage access, reimbursement, and site-of-care logistics.
Buy PEMGARDA for resale and distribution to sites of care; important because they handle channel access and logistics.
Purchase directly or through distributors to administer PEMGARDA in outpatient settings.
Hospitals, clinics, and provider groups that buy and administer the product for eligible patients.
Not direct product customers, but they determine net realization through coverage and billing rules.
Strategia
Invivyd’s strategy is to build a commercial franchise around PEMGARDA while advancing next-generation monoclonal antibodies that can keep pace with viral evolution. The company is also expanding its sales, marketing, market access, and distribution capabilities so it can support commercialization without relying entirely on external partners.
Current revenue depends on adoption of the first authorized product and access to sites of care.
The company needs sales, marketing, and market access capacity to support product uptake and future launches.
Pipeline diversification reduces dependence on a single authorized product and addresses viral evolution risk.
Commercial continuity depends on third-party CDMO access and uninterrupted supply of biologic product.
Maantiede
Invivyd’s commercial revenue is currently concentrated in the United States, where PEMGARDA is sold under a traditional commercial distribution model. The company also maintains trademark filings and registrations in several international markets, but its operating and revenue footprint remains overwhelmingly U.S.-centric.
Riskit
Invivyd faces the classic risks of an early commercial-stage biotech: dependence on a single authorized product, uncertain market uptake, and heavy reliance on external manufacturing and distribution partners. The company also disclosed substantial doubt about its ability to continue as a going concern, making financing access and Nasdaq compliance especially important near-term risks.
- Going concern and liquidity shortfallVaikutus: KriittinenTodennäköisyys: Korkea
Management disclosed that existing cash may not fund operations beyond one year without additional revenue or financing.
Kohdistuu: Operating runway and ability to fund commercialization and R&D
- Single-product concentrationVaikutus: KorkeaTodennäköisyys: Korkea
Current product revenue is tied primarily to PEMGARDA, so demand or reimbursement weakness would directly hit sales.
Kohdistuu: Revenue concentration
- Manufacturing and supply chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third-party manufacturers and CDMOs, including foreign contract manufacturers that may face trade or regulatory restrictions.
Kohdistuu - Regulatory and scientific obsolescenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Antibody effectiveness can be undermined by viral evolution, which can reduce clinical and commercial relevance.
Kohdistuu: Product efficacy and authorization durability
- Nasdaq listing complianceVaikutus: KeskitasoTodennäköisyys: Matala
The company previously received a minimum bid price deficiency notice and could face future listing pressure if market conditions weaken.
Kohdistuu: Capital markets access and trading liquidity
Kirjanpito
Harkinnanvaraiset erätPEMGARDA revenue is recognized on transfer of control but netted for discounts, distributor fees, chargebacks, returns, and co-pay support.
Vaikutus: Can materially change reported product revenue and gross-to-net deductions
Management estimates product remaining in the distribution channel and updates reserves quarterly.
Vaikutus: Affects revenue timing and period-to-period comparability
Liquidity assumptions underpin the company’s ability to continue operations and may affect disclosure and valuation.
Vaikutus: Signals financing risk and uncertainty in future operating plans
Clinical development, procurement, and manufacturing costs are expensed as incurred and depend on external vendors.
Vaikutus: Can create lumpy operating expense patterns and estimate sensitivity
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Inhibrx Biosciences, Inc.
INBX · Biological Products, (No Diagnostic Substances)
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
BioVie Inc
BIVIW · Pharmaceutical Preparations
Päivitetty: 24.9.2026